In B16F10 tumor-bearing mice the highest amount of tumor specific GrB+/IFNγ+ immune cells was determined in mice receiving combinatorial treatment, while in CT26 tumor-bearing mice, no significant changes were observed in the amount of tumor specific GrB+/IFNγ+ immune cells regardless of the administered therapy (Figure 4). This evidence concerns the gene GZMB and neoplasm.